ACAD ACADIA Pharmaceuticals Forecast, Technical & Fundamental Analysis
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world... Show more
ACAD is expected to report earnings to rise 207.50% to 6 cents per share on August 11
Q2'26
Est.
$0.06
Q1'26
Missed
by $0.03
Q4'25
Beat
by $1.46
Q3'25
Beat
by $0.28
Q2'25
Beat
by $0.02
The last earnings report on May 06 showed earnings per share of 1 cents, missing the estimate of 5 cents. With 306.38K shares outstanding, the current market capitalization sits at 3.78B.
A.I. Advisor
published General Information
General Information
a developer of pharmaceuticals drugs for treatment of central nervous system disorders
A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with STTK. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then STTK could also see price increases.
ACAD in upward trend: price rose above 50-day moving average on June 22, 2026
ACAD moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend. In of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where ACAD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ACAD as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ACAD just turned positive on June 17, 2026. Looking at past instances where ACAD's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACAD advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
ACAD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for ACAD crossed bearishly below the 50-day moving average on May 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ACAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.031) is normal, around the industry mean (20.966). P/E Ratio (9.995) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ACAD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (3.453) is also within normal values, averaging (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
